‍ ‍

Flaxseed Meal : Research

Overview

‍ ‍

This page provides a curated overview of selected peer-reviewed human studies examining flaxseed, particularly ground or milled whole flaxseed. The goal is to provide transparent access to clinically relevant research addressing cardiovascular and lipid biomarkers, blood pressure, glucose and insulin-related outcomes, bowel function, satiety, body composition, and the influence of flaxseed processing on bioavailability.

Important Context for Readers

Scientific studies examine outcomes in defined populations under specific research conditions. Results from individual trials may not apply to all individuals. Flaxseed studies also differ substantially in formulation, including ground or milled whole flaxseed, intact seed, flaxseed oil, lignan extracts, and isolated flaxseed fiber. These forms should not be assumed to produce equivalent effects. The studies below are presented for educational purposes and should not be interpreted as treatment recommendations.

‍Summary of Evidence

Across randomized trials and meta-analyses, flaxseed has been associated with modest average changes in lipid and blood-pressure biomarkers, with greater consistency for whole or ground flaxseed than for flaxseed oil in several analyses. Glycemic findings are less consistent: pooled studies suggest small improvements in fasting glucose and insulin-resistance measures, while effects on HbA1c vary according to population and analysis. Evidence for bowel regularity comes from smaller trials, whereas pooled evidence suggests small average reductions in body weight and waist circumference. Human bioavailability studies support milling or grinding flaxseed rather than consuming the seed intact.

‍Key Areas of Research

Absorption and Metabolism

1) Austria JA, Richard MN, Chahine MN, et al. Bioavailability of alpha-linolenic acid in subjects after ingestion of three different forms of flaxseed. J Am Coll Nutr. 2008.

PMID: 18689552

DOI: https://doi.org/10.1080/07315724.2008.10719693

Population: Healthy male and female participants.

Design: Randomized clinical study comparing 30 g/day whole flaxseed, 30 g/day milled flaxseed, and flaxseed oil providing 6 g ALA, delivered in baked foods over 3 months.

Key findings:

  • Milled flaxseed significantly increased circulating ALA

  • Flaxseed oil also increased circulating ALA

  • Intact whole flaxseed did not produce a significant increase in plasma ALA

  • EPA and DHA concentrations did not significantly increase

  • Early gastrointestinal discomfort occurred across groups but persisted more prominently with intact whole seed

  • Compliance was poorer with whole intact flaxseed than with milled seed

2) Kuijsten A, Arts ICW, van't Veer P, et al. The relative bioavailability of enterolignans in humans is enhanced by milling and crushing of flaxseed. J Nutr. 2005.

PMID: 16317125

DOI: https://doi.org/10.1093/jn/135.12.2812

Population: 12 healthy participants.

Design: Randomized crossover study comparing whole, crushed, and ground flaxseed at 0.3 g/kg body weight/day, each for 10 days.

Key findings:

  • Ground flaxseed produced the greatest enterolignan exposure

  • Relative enterolignan bioavailability from whole flaxseed was approximately 28% of that from ground flaxseed

  • Relative bioavailability from crushed flaxseed was approximately 43% of that from ground flaxseed

  • Milling therefore materially increased access to flaxseed lignans‍

Cardiovascular and Lipid Support

Evidence strength: Moderate.

Multiple randomized trials and meta-analyses have evaluated LDL cholesterol, total cholesterol, triglycerides, and blood pressure. The evidence supports modest average biomarker effects, with substantial heterogeneity across populations, formulations, doses, and study durations.

‍3) Hadi A, Askarpour M, Salamat S, et al. Effect of flaxseed supplementation on lipid profile: An updated systematic review and dose-response meta-analysis of sixty-two randomized controlled trials. Pharmacol Res. 2020.

‍PMID: 31899314

DOI: https://doi.org/10.1016/j.phrs.2019.104622

Population: 3,772 participants across 62 randomized controlled trials evaluating flaxseed and flaxseed-derived interventions.

‍Design: Systematic review and dose-response meta-analysis of randomized controlled trials.

Key findings:

  • Mean LDL-C reduction was approximately 4.2 mg/dL

  • Total cholesterol decreased approximately 5.4 mg/dL

  • Triglycerides decreased approximately 9.4 mg/dL

  • No significant average change in HDL-C was identified

  • Considerable variation existed among formulations, populations, doses, and trial durations

4) Yang C, Xia H, Wan M, et al. Comparisons of the effects of different flaxseed products consumption on lipid profiles, inflammatory cytokines and anthropometric indices in patients with dyslipidemia related diseases: systematic review and a dose-response meta-analysis of randomized controlled trials. Nutr Metab (Lond). 2021.

PMID: 34635132

DOI: https://doi.org/10.1186/s12986-021-00619-3

Population: 1,698 participants across 31 randomized controlled trials involving dyslipidemia-related conditions.

Design: Systematic review and dose-response meta-analysis comparing whole flaxseed, flaxseed oil, and lignan preparations.

Key findings:

  • Whole flaxseed was associated with mean reductions of approximately 11.9 mg/dL in total cholesterol, 10.5 mg/dL in LDL-C, and 19.8 mg/dL in triglycerides

  • Whole flaxseed also reduced apolipoprotein B in pooled analyses

  • Flaxseed oil did not reproduce the lipid effects observed with whole flaxseed

  • Findings support the importance of distinguishing ground/whole flaxseed from flaxseed oil and isolated constituents

  • Subgroup and dose-response results should be interpreted cautiously because of between-study differences

5) Li L, Li H, Gao Y, et al. Effect of flaxseed supplementation on blood pressure: a systematic review, and dose-response meta-analysis of randomized clinical trials. Food Funct. 2023.

PMID: 36622248

DOI: https://doi.org/10.1039/D2FO02566C

Population: 2,427 participants across 33 randomized trials comprising 43 treatment arms.

Design: Systematic review and dose-response meta-analysis of randomized clinical trials evaluating flaxseed supplementation and blood pressure.

Key findings:

  • Mean systolic blood-pressure reduction was approximately 3.19 mmHg

  • Mean diastolic reduction was approximately 2.61 mmHg

  • Greater reductions were observed in trials lasting more than 20 weeks

  • Greater effects were also reported with flaxseed doses of ≥30 g/day and among participants with hypertension

  • Effects were statistically heterogeneous across studies, with substantial variability in populations, formulations, doses, and study duration

6) Rodriguez-Leyva D, Weighell W, Edel AL, et al. Potent antihypertensive action of dietary flaxseed in hypertensive patients. Hypertension. 2013.

PMID: 24126178

DOI: https://doi.org/10.1161/HYPERTENSIONAHA.113.02094

Population: 110 adults with peripheral artery disease, many of whom had hypertension.

Design: Prospective, double-blind, randomized, placebo-controlled trial using foods containing 30 g/day of milled flaxseed for 6 months.

Key findings:

  • Systolic pressure was approximately 10 mmHg lower and diastolic pressure approximately 7 mmHg lower versus placebo at 6 months

  • Among participants entering with systolic pressure ≥140 mmHg, systolic pressure decreased approximately 15 mmHg and diastolic pressure approximately 7 mmHg from baseline

  • Circulating ALA and enterolignan concentrations increased substantially

  • The magnitude of this effect is substantially greater than pooled meta-analytic estimates and should not be considered the expected response for all individuals

7) Kunutsor SK, Jassal DS, Ravandi A, et al. Dietary flaxseed: cardiometabolic benefits and its role in promoting healthy aging. GeroScience. 2025.

PMID: 39821819

DOI: https://doi.org/10.1007/s11357-025-01512-0

Population: Human studies examining flaxseed across populations with varying cardiometabolic risk, including individuals with hypertension, dyslipidemia, type 2 diabetes, metabolic syndrome, and other cardiometabolic conditions.

Design: Comprehensive narrative review synthesizing clinical and mechanistic evidence on flaxseed, cardiometabolic risk factors, clinical outcomes, and biological processes relevant to healthy aging.

Key findings:

  • Flaxseed consumption was associated across the reviewed literature with favorable changes in lipid levels, blood pressure, glycemic measures, body weight, and BMI

  • Reported blood-pressure reductions across studies ranged from approximately 2–15 mmHg systolic and 1–7 mmHg diastolic, with effects influenced by baseline risk, dose, and intervention duration

  • The authors concluded that the most consistent cardiometabolic benefits appeared with ground whole flaxseed at ≥30 g/day for at least 12 weeks, particularly among individuals with elevated cardiometabolic risk

  • Flaxseed's principal constituents—ALA, lignans, and soluble fiber—may contribute complementary effects on lipid metabolism, glucose regulation, inflammation, oxidative stress, and vascular function

  • Evidence for improvement in cardiometabolic risk factors is substantially stronger than evidence for prevention of cardiovascular disease, diabetes, chronic kidney disease, or other clinical outcomes

  • The authors emphasized that direct evidence demonstrating prevention of major cardiometabolic diseases or improved longevity remains limited and that additional long-term clinical research is needed

Metabolic Support          

‍Evidence strength: Low to Moderate.

‍Randomized trials and pooled analyses suggest possible effects on fasting glucose, insulin, and insulin-resistance measures, but findings for HbA1c and other metabolic endpoints remain inconsistent.

8) Mohammadi-Sartang M, Sohrabi Z, Barati-Boldaji R, et al. Flaxseed supplementation on glucose control and insulin sensitivity: a systematic review and meta-analysis of 25 randomized, placebo-controlled trials. Nutr Rev. 2018.

PMID: 29228348

DOI: https://doi.org/10.1093/nutrit/nux052

Population: Adults across 25 randomized clinical trials comprising 30 treatment arms.

Design: Systematic review and meta-analysis examining glucose, insulin, HOMA-IR, QUICKI, and HbA1c.

Key findings:

  • Fasting glucose decreased by approximately 2.94 mg/dL

  • Insulin concentrations decreased modestly

  • HOMA-IR improved in pooled analysis

  • QUICKI improved

  • No significant overall effect on HbA1c was identified

  • Subgroup effects were more favorable for whole flaxseed than for flaxseed oil or isolated lignans

9) Villarreal-Renteria AI, Herrera-Echauri DD, Rodríguez-Rocha NP, et al. Effect of flaxseed (Linum usitatissimum) supplementation on glycemic control and insulin resistance in prediabetes and type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Complement Ther Med. 2022.

PMID: 35843472

DOI: https://doi.org/10.1016/j.ctim.2022.102852

Population: Adults with prediabetes or type 2 diabetes.

Design: Systematic review and meta-analysis of seven studies specifically evaluating milled or ground flaxseed.

Key findings:

  • Pooled analyses reported favorable standardized effects on fasting glucose

  • Insulin concentrations and HOMA-IR improved

  • HbA1c was significantly reduced in this restricted analysis

  • Only seven studies were available

  • Method of supplementation, dose, and accompanying dietary interventions varied

  • Authors emphasized the need for additional randomized trials

10) Xi H, Zhou W, Sohaib M, et al. Flaxseed supplementation significantly reduces hemoglobin A1c in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Nutr Res. 2023.

PMID: 36640581

DOI: https://doi.org/10.1016/j.nutres.2022.12.008

Population: Adults with type 2 diabetes across 13 randomized controlled studies.

Design: Systematic review and meta-analysis of randomized trials.

Key findings:

  • HbA1c was significantly reduced in pooled analysis

  • No significant overall effect was found for fasting glucose, HOMA-IR, body weight, BMI, or blood pressure

  • Subgroup analyses suggested greater glycemic effects among participants with poorer baseline glycemic control

  • Whole-flaxseed subgroups showed some favorable lipid findings

  • Results differ from broader meta-analyses that found no significant overall HbA1c effect

‍Other Support

‍Evidence: Low to Moderate.

Evidence for body composition is supported by numerous trials but the average effect is small and heterogeneous. Evidence for bowel regularity and acute satiety is more limited and comes from smaller or specialized populations.

11) Musazadeh V, Abolghasemian M, Kavyani Z, et al. The effects of flaxseed (Linum usitatissimum) supplementation on anthropometric indices: An updated systematic review and meta-analysis of randomized clinical trials. Complement Ther Med. 2024.

PMID: 38992480

DOI: https://doi.org/10.1016/j.ctim.2024.103066

Population: Participants across 64 trials comprising 72 intervention arms.

Design: Updated systematic review and random-effects meta-analysis evaluating body weight, BMI, and waist circumference.

Key findings:

  • Mean body-weight reduction was approximately 0.63 kg

  • BMI decreased approximately 0.24 kg/m²

  • Waist circumference decreased approximately 1.43 cm

  • Statistical heterogeneity was substantial

  • GRADE assessment characterized the anthropometric findings as moderate-certainty evidence

  • Effects were larger in some longer-duration and higher-BMI subgroups

12) Soltanian N, Janghorbani M. A randomized trial of the effects of flaxseed to manage constipation, weight, glycemia, and lipids in constipated patients with type 2 diabetes. Nutr Metab (Lond). 2018.

PMID: 29760761

DOI: https://doi.org/10.1186/s12986-018-0273-z

Population: 53 adults with type 2 diabetes and chronic constipation.

Design: Single-blind randomized controlled trial comparing placebo cookies with cookies containing 5 g flaxseed twice daily (10 g/day) for 12 weeks.

Key findings:

  • Constipation symptom scores improved significantly relative to placebo

  • The intervention also produced favorable changes in several weight, glycemic, and lipid measures

  • Compliance was reported as good

  • No adverse effects were reported during the trial

  • The population was small and clinically specific, limiting generalizability to otherwise healthy adults with constipation

13) Ibrügger S, Kristensen M, Mikkelsen MS, et al. Flaxseed dietary fiber supplements for suppression of appetite and food intake. Appetite. 2012.

PMID: 22245724

DOI: https://doi.org/10.1016/j.appet.2011.12.024

Population: Healthy adults participating in two acute randomized crossover experiments with 24 and 20 subjects.

Design: Single-blind randomized crossover studies evaluating a flaxseed-fiber drink and flaxseed-fiber tablets supplying approximately 2.5 g soluble fiber.

Key findings:

  • The flax-fiber drink increased subjective satiety and fullness compared with control

  • Subsequent ad-libitum energy intake was lower after the flax drink

  • Appetite responses were similar between flax-fiber tablets and the flax-fiber drink

  • This was an acute study of isolated flaxseed fiber, not ground whole flaxseed meal

  • Findings therefore provide supportive evidence for satiety mechanisms but should not be directly extrapolated to long-term weight loss from flaxseed meal

Educational Notice
These summaries are provided for educational purposes to review published scientific literature and should not be interpreted as medical advice, diagnosis, or treatment recommendations. Readers should consult qualified healthcare professionals for personal medical decisions.

‍FDA Disclaimer:
These statements have not been evaluated by the U.S. Food and Drug Administration. Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease.

‍FTC Affiliate Disclosure
‍Some pages on this website may contain affiliate links to products. If readers choose to purchase through those links, the site may receive a commission. Affiliate relationships do not influence the selection or discussion of scientific studies summarized on this reference page.